Regeneron Pharmaceuticals, Inc.
REGNNext catalyst
Dupilumab
Atopic Dermatitis (AD)
Get an email about REGN's next catalysts
Track Regeneron Pharmaceuticals (REGN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 31 more upcoming events in our data (earnings, Phase 2 readout, PDUFA date and more).See the timeline
33 upcoming, 5 past
REGN Earnings Report
EPS Est: $13.76 | FQ end Sep/2026 | Call: bmo
Dupilumab Phase 2 Est. Readout
Estimated primary completion for Dupilumab trial (NCT05720325) in Asthma, Allergic. Topline data typically follows completion by weeks to months.
Sourcecemiplimab Phase 2 Est. Readout
Primary completion for cemiplimab trial (NCT06190951) in Melanoma
SourceCemiplimab Phase 3 Est. Readout
Primary completion for Cemiplimab trial (NCT03969004) in Cutaneous Squamous Cell Carcinoma
Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo in high-risk CSCC
SourceOlatorepatide Phase 2 Est. Readout
Estimated primary completion for Olatorepatide trial (NCT07431086) in Overweight or Obesity. Topline data typically follows completion by weeks to months.
SourceREGN2810 Phase 2 Est. Readout
Estimated primary completion for REGN2810 trial (NCT03951831) in Prostate Cancer Metastatic. Topline data typically follows completion by weeks to months.
SourceFDA PDUFA Date cemdisiran
For Anti-AChR antibody-positive generalized myasthenia gravis. NDA, Priority Review; company gives November 2026, no exact day. Verified against the company announcement on 2026-10-16.
SourceREGN7999 Phase 2 Est. Readout (FERVENT-1)
Primary completion for REGN7999 trial (NCT06421636) in Non-Transfusion Dependent Beta-Thalassemia (NTDT)
SourceHow REGN's past catalysts played out
Market Overview
Stock performance and key metrics
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap.
WebsiteDupixent
Dupilumab
Atopic Dermatitis
ranibizumab
Macular Degeneration
mibavademab
Generalized Lipodystrophy
Suptavumab
Respiratory Syncytial Virus Infections
REGN7508
Venous Thromboembolism (VTE)
REGN9933
Venous Thromboembolism
Oral corticosteroids (OCS)
Bullous Pemphigoid
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
Diabetic Macular Edema
REGN1908
Allergic Conjunctivitis
Alirocumab
Homozygous Familial Hypercholesterolemia
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
Branch Retinal Vein Occlusion
Statin
Hypercholesterolemia
Sarilumab
COVID-19
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Macular Degeneration
Intravitreal Aflibercept
Neovascular Age-related Macular Degeneration
LMT (atorvastatin, simvastatin, or rosuvastatin)
Heterozygous Familial Hypercholesterolemia
REGN-2Cat
Allergic Conjunctivitis
REGN10933 + REGN10987
Healthy Participants
Rivaroxaban
Peripheral Artery Disease (PAD)
Dupilumab
Atopic Dermatitis (AD)
REGN5715
Allergic Conjunctivitis
Odronextamab
Diffuse Large B-cell Lymphoma (DLBCL)
REGN475
Sciatica
REGN2810
Non-small Cell Lung Cancer
Acetylsalicylic Acid (ASA)
Symptomatic Venous Thromboembolism (VTE)
aflibercept
Diabetic Macular Edema
REGN5713
Allergic Rhinitis
Fluorouracil
Colorectal Cancer Metastatic
Atorvastatin
Hypercholesterolemia
Indomethacin
Acute Gout Flare
Cemdisiran
Paroxysmal Nocturnal Hemoglobinuria
Folic acid
Rheumatoid Arthritis
2-mg Intravitreous Aflibercept Injection
Proliferative Diabetic Retinopathy
Rilonacept
Gout
Eylea (Aflibercept, BAY86-5321)
Retinopathy of Prematurity (ROP)
Prompt aflibercept
Diabetic Macular Edema
Simvastatin
Hypercholesterolemia
Investigator Choice (IC) Chemotherapy
Squamous Cell Carcinoma (SCC)
Non-statin Lipid-Modifying Therapy
Hypercholesterolemia
aflibercept PFS
Diabetic Macular Edema (DME)
cemiplimab
Advanced Cutaneous Squamous Cell Carcinoma
REGN5714
Allergic Rhinitis
Dupilumab Prefilled Syringe
Asthma Control
Prednisone/Prenisolone
Follicular Lymphoma (FL)
Elotuzumab
Relapsed Refractory Multiple Myeloma (RRMM)
Garetosmab
Fibrodysplasia Ossificans Progressiva
Fasinumab
Osteoarthritis of the Knee or Hip
VEGF Trap-Eye (BAY86-5321)
Diabetes Mellitus
Albuterol/Salbutamol
Asthma
Pozelimab + Cemdisiran
Generalized Myasthenia Gravis
sulfasalazine
Rheumatoid Arthritis
Nicotinic acid
Hypercholesterolaemia
Ramucirumab
Recurrent Lung Non-Small Cell Carcinoma
Deferred aflibercept
Diabetic Retinopathy
Libtayo
Cemiplimab
Non-Small Cell Lung Cancer
Etoposide Phosphate
B-cell Non Hodgkin Lymphoma
Omega-3 fatty acids
Hypercholesterolaemia
Evinacumab
Hypercholesterolemia
Lovastatin
Hypercholesterolaemia
Cholestyramine
Hypercholesterolaemia
CAR T-cells (TBC)
B-cell Non Hodgkin Lymphoma
Linvoseltamab
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Naproxen
Osteoarthritis, Knee
Fianlimab
Melanoma
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Macular Edema
Ravulizumab
Paroxysmal Nocturnal Hemoglobinuria
Intravitreal Aflibercept Injection (IAI)
Neovascular Age-Related Macular Degeneration
VEGF Trap-Eye
Macular Edema Secondary to Central Retinal Vein Occlusion
Inhaled Long-Acting Beta Agonist
Chronic Obstructive Pulmonary Disease
Intravitreal Aflibercept Injection
Diabetic Macular Edema
Inhaled Corticosteroid
Chronic Obstructive Pulmonary Disease
Inhaled Long-Acting Muscarinic Antagonist
Chronic Obstructive Pulmonary Disease
Suptavumab - 2 Doses
Respiratory Syncytial Virus Infections
Suptavumab - 1
Respiratory Syncytial Virus Infections
Levalbuterol/Levosalbutamol
Asthma
Pozelimab
CD55-deficient Protein-losing Enteropathy
Trevogrumab-Part B and Part C
Obesity
Encorafenib + Binimetinib
Melanoma BRAF V600E/K Mutated
Fluticasone or Fluticasone/salmeterol combination
Asthma
Platinum based chemotherapy
Carcinoma, Non-Small-Cell Lung
cemiplimab plus fianlimab
Colo-rectal Cancer
Cemiplimab-Rwlc
Non-small Cell Lung Cancer Stage III
Fluticasone/Salmeterol combination therapy
Asthma
Chimeric Antigen Receptor T-Cell Therapy
Recurrent Diffuse Large B-Cell Lymphoma
Topical imiquimod
Cutaneous Basal Cell Carcinoma
Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept
Thyroid Eye Disease
Sarilumab, SAR153191 IV
Rheumatoid Arthritis
cemiplimab + REGN7075
Colo-rectal Cancer
REGN17372+Linvoseltamab
Relapsed Refractory Multiple Myeloma (RRMM)
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]
Ovarian Cancer
REGN5458
Multiple Myeloma
REGN4336
Metastatic Castration-resistant Prostate Cancer
ALN-ANG3
Diabetic Kidney Disease (DKD)
High-dose aflibercept
Neovascular (Wet) Age-Related Macular Degeneration
REGN5678
Metastatic Castration-resistant Prostate Cancer
REGN15505
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
FLT PET/CT
Prostate Cancer
S095024
Non-small Cell Lung Cancer (NSCLC)
SAR440340
Chronic Obstructive Pulmonary Disease
pTVG-AR
Prostate Cancer
S095018 Recommended Dose Expansion (RDE)
Non-small Cell Lung Cancer (NSCLC)
S095024 RDE
Non-small Cell Lung Cancer (NSCLC)
S095029
Non-small Cell Lung Cancer (NSCLC)
S095029 RDE
Non-small Cell Lung Cancer (NSCLC)
REGN7075
Advanced Solid Tumors
REGN22530
Primary Open Angle Glaucoma (POAG)
REGN7041
Active Noninfectious Uveitis Affecting the Posterior Segment
REGN1908-1909
Cat Allergy
Marlotamig
Non-Small Cell Lung Cancer
REGN5668
Ovarian Cancer
Platinum-based chemotherapy
Non-Small Cell Lung Cancer
REGN7544
Postural Orthostatic Tachycardia Syndrome (POTS)
VEGF Trap Eye
Macular Degeneration
REGN10933+REGN10987 combination therapy
COVID-19
REGN910-3
Diabetic Macular Edema
REGN7945+Linvoseltamab
Relapsed/Refractory Multiple Myeloma
Low-Dose REGN4461
Generalized Lipodystrophy
REGN10597
Melanoma
REGN1500
Homozygous Familial Hypercholesterolemia
AR101
Peanut Allergy
REGN3918
Paroxysmal Nocturnal Hemoglobinuria (PNH)
ALN-CFB
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Olatorepatide
Overweight or Obesity
REGN2477
Fibrodysplasia Ossificans Progressiva
Timothy Grass SCIT
Allergic Rhinitis
casirivimab+imdevimab
Healthy
PB
Sepsis-Induced Hypotension
REGN5381
Heart Failure
REGV131
Hemophilia B
REGN7999
Non-Transfusion Dependent Beta-Thalassemia (NTDT)
ISA101b
Cervical Cancer
Fixed Dose Combination (FDC) cemiplimab+fianlimab
Melanoma
REGN1033 (SAR391786)
Sarcopenia
Vonsetamig
Chronic Kidney Disease (CKD)
REGN5093
NSCLC
Ubamatamab
Ovarian Cancer
REGN5459
Relapsed Multiple Myeloma
ALN-SOD
Amyotrophic Lateral Sclerosis (ALS)
REGN13335
Pulmonary Arterial Hypertension (PAH)
Trevogrumab-Part A
Obesity
BNT116
Advanced Non-Small Cell Lung Cancer
Tocilizumab
Recurrent Ovarian Cancer
ALN-HSD
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Platinum Doublet
Non-small Cell Lung Cancer
REGN15505+Cemiplimab
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
ALN-CIDEB
Metabolic Dysfunction-Associated Steatotic Liver Disease
ALN-PNP
Healthy Volunteers
FDC fianlimab+cemiplimab
Head and Neck Squamous Cell Carcinoma (HNSCC)
Aflibercept Injection
Diabetic Retinopathy
Cemiplimab i.v. on day 1 of cycle
Merkel Cell Carcinoma, Stage I
Pemetrexed (Alimta)
Pleural Mesotheliomas
Enoxaparin
Venous Thromboembolism
Cemiplimab Plus Gemcitabine
Pancreatic Ductal Adenocarcinoma (mPDAC)
ZIV-Aflibercept
Metastatic Uveal Melanoma
Sirolimus
Cutaneous Squamous Cell Carcinoma
Aspirin Challenge
Aspirin-exacerbated Respiratory Disease
RP1
Cutaneous Squamous Cell Carcinoma
Motixafortide
Pancreatic Cancer
Pexastimogene Devacirepvec (Pexa-Vec)
Renal Cell Carcinoma
Platinum Doublet Chemotherapy (PDC)
NSCLC
VV1
Melanoma
Dupilumab (blinded)
Eosinophilic Gastritis
Cemiplimab Intravenous
Clear Cell Renal Cell Carcinoma
Carboplatin (AUC 5)
Pleural Mesotheliomas
REGN15505+REGN4336
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Dupixent Dupilumab | Approved | Atopic Dermatitis | - | - |
ranibizumab | Phase 3 | Macular Degeneration | - | - |
mibavademab | Phase 3 | Generalized Lipodystrophy | - | - |
Suptavumab | Phase 3 | Respiratory Syncytial Virus Infections | - | - |
REGN7508 | Phase 3 | Venous Thromboembolism (VTE) | - | - |
REGN9933 | Phase 3 | Venous Thromboembolism | - | - |
Oral corticosteroids (OCS) | Phase 3 | Bullous Pemphigoid | - | - |
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) | Phase 3 | Diabetic Macular Edema | - | - |
REGN1908 | Phase 3 | Allergic Conjunctivitis | - | - |
Alirocumab | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) | Phase 3 | Branch Retinal Vein Occlusion | - | - |
Statin | Phase 3 | Hypercholesterolemia | - | - |
Sarilumab | Phase 3 | COVID-19 | - | - |
aflibercept injection (VEGF Trap-Eye, BAY86-5321) | Phase 3 | Macular Degeneration | - | - |
Intravitreal Aflibercept | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
LMT (atorvastatin, simvastatin, or rosuvastatin) | Phase 3 | Heterozygous Familial Hypercholesterolemia | - | - |
REGN-2Cat | Phase 3 | Allergic Conjunctivitis | - | - |
REGN10933 + REGN10987 | Phase 3 | Healthy Participants | - | - |
Rivaroxaban | Phase 3 | Peripheral Artery Disease (PAD) | - | - |
Dupilumab | Phase 3 | Atopic Dermatitis (AD) | - | - |
REGN5715 | Phase 3 | Allergic Conjunctivitis | - | - |
Odronextamab | Phase 3 | Diffuse Large B-cell Lymphoma (DLBCL) | - | - |
REGN475 | Phase 3 | Sciatica | - | - |
REGN2810 | Phase 3 | Non-small Cell Lung Cancer | - | - |
Acetylsalicylic Acid (ASA) | Phase 3 | Symptomatic Venous Thromboembolism (VTE) | - | - |
aflibercept | Phase 3 | Diabetic Macular Edema | - | - |
REGN5713 | Phase 3 | Allergic Rhinitis | - | - |
Fluorouracil | Phase 3 | Colorectal Cancer Metastatic | - | - |
Atorvastatin | Phase 3 | Hypercholesterolemia | - | - |
Indomethacin | Phase 3 | Acute Gout Flare | - | - |
Cemdisiran | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Folic acid | Phase 3 | Rheumatoid Arthritis | - | - |
2-mg Intravitreous Aflibercept Injection | Phase 3 | Proliferative Diabetic Retinopathy | - | - |
Rilonacept | Phase 3 | Gout | - | - |
Eylea (Aflibercept, BAY86-5321) | Phase 3 | Retinopathy of Prematurity (ROP) | - | - |
Prompt aflibercept | Phase 3 | Diabetic Macular Edema | - | - |
Simvastatin | Phase 3 | Hypercholesterolemia | - | - |
Investigator Choice (IC) Chemotherapy | Phase 3 | Squamous Cell Carcinoma (SCC) | - | - |
Non-statin Lipid-Modifying Therapy | Phase 3 | Hypercholesterolemia | - | - |
aflibercept PFS | Phase 3 | Diabetic Macular Edema (DME) | - | - |
cemiplimab | Phase 3 | Advanced Cutaneous Squamous Cell Carcinoma | - | - |
REGN5714 | Phase 3 | Allergic Rhinitis | - | - |
Dupilumab Prefilled Syringe | Phase 3 | Asthma Control | - | - |
Prednisone/Prenisolone | Phase 3 | Follicular Lymphoma (FL) | - | - |
Elotuzumab | Phase 3 | Relapsed Refractory Multiple Myeloma (RRMM) | - | - |
Garetosmab | Phase 3 | Fibrodysplasia Ossificans Progressiva | - | - |
Fasinumab | Phase 3 | Osteoarthritis of the Knee or Hip | - | - |
VEGF Trap-Eye (BAY86-5321) | Phase 3 | Diabetes Mellitus | - | - |
Albuterol/Salbutamol | Phase 3 | Asthma | - | - |
Pozelimab + Cemdisiran | Phase 3 | Generalized Myasthenia Gravis | - | - |
sulfasalazine | Phase 3 | Rheumatoid Arthritis | - | - |
Nicotinic acid | Phase 3 | Hypercholesterolaemia | - | - |
Ramucirumab | Phase 3 | Recurrent Lung Non-Small Cell Carcinoma | - | - |
Deferred aflibercept | Phase 3 | Diabetic Retinopathy | - | - |
Libtayo Cemiplimab | Phase 3 | Non-Small Cell Lung Cancer | Fast Track | - |
Etoposide Phosphate | Phase 3 | B-cell Non Hodgkin Lymphoma | - | - |
Omega-3 fatty acids | Phase 3 | Hypercholesterolaemia | - | - |
Evinacumab | Phase 3 | Hypercholesterolemia | - | - |
Lovastatin | Phase 3 | Hypercholesterolaemia | - | - |
Cholestyramine | Phase 3 | Hypercholesterolaemia | - | - |
CAR T-cells (TBC) | Phase 3 | B-cell Non Hodgkin Lymphoma | - | - |
Linvoseltamab | Phase 3 | Monoclonal Gammopathy of Undetermined Significance (MGUS) | - | - |
Naproxen | Phase 3 | Osteoarthritis, Knee | - | - |
Fianlimab | Phase 3 | Melanoma | - | - |
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Phase 3 | Macular Edema | - | - |
Ravulizumab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Intravitreal Aflibercept Injection (IAI) | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
VEGF Trap-Eye | Phase 3 | Macular Edema Secondary to Central Retinal Vein Occlusion | - | - |
Inhaled Long-Acting Beta Agonist | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Intravitreal Aflibercept Injection | Phase 3 | Diabetic Macular Edema | - | - |
Inhaled Corticosteroid | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Inhaled Long-Acting Muscarinic Antagonist | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Suptavumab - 2 Doses | Phase 3 | Respiratory Syncytial Virus Infections | - | - |
Suptavumab - 1 | Phase 3 | Respiratory Syncytial Virus Infections | - | - |
Levalbuterol/Levosalbutamol | Phase 3 | Asthma | - | - |
Pozelimab | Phase 3 | CD55-deficient Protein-losing Enteropathy | - | - |
Trevogrumab-Part B and Part C | Phase 2 | Obesity | - | - |
Encorafenib + Binimetinib | Phase 2 | Melanoma BRAF V600E/K Mutated | - | - |
Fluticasone or Fluticasone/salmeterol combination | Phase 2 | Asthma | - | - |
Platinum based chemotherapy | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
cemiplimab plus fianlimab | Phase 2 | Colo-rectal Cancer | - | - |
Cemiplimab-Rwlc | Phase 2 | Non-small Cell Lung Cancer Stage III | - | - |
Fluticasone/Salmeterol combination therapy | Phase 2 | Asthma | - | - |
Chimeric Antigen Receptor T-Cell Therapy | Phase 2 | Recurrent Diffuse Large B-Cell Lymphoma | - | - |
Topical imiquimod | Phase 2 | Cutaneous Basal Cell Carcinoma | - | - |
Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept | Phase 2 | Thyroid Eye Disease | - | - |
Sarilumab, SAR153191 IV | Phase 2 | Rheumatoid Arthritis | - | - |
cemiplimab + REGN7075 | Phase 2 | Colo-rectal Cancer | - | - |
REGN17372+Linvoseltamab | Phase 2 | Relapsed Refractory Multiple Myeloma (RRMM) | - | - |
Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] | Phase 2 | Ovarian Cancer | - | - |
REGN5458 | Phase 2 | Multiple Myeloma | OrphanFast TrackBreakthrough | - |
REGN4336 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
ALN-ANG3 | Phase 2 | Diabetic Kidney Disease (DKD) | - | - |
High-dose aflibercept | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration | - | - |
REGN5678 | Phase 2 | Metastatic Castration-resistant Prostate Cancer | - | - |
REGN15505 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | - | - |
FLT PET/CT | Phase 2 | Prostate Cancer | - | - |
S095024 | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
SAR440340 | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
pTVG-AR | Phase 2 | Prostate Cancer | - | - |
S095018 Recommended Dose Expansion (RDE) | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
S095024 RDE | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
S095029 | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
S095029 RDE | Phase 2 | Non-small Cell Lung Cancer (NSCLC) | - | - |
REGN7075 | Phase 2 | Advanced Solid Tumors | - | - |
REGN22530 | Phase 2 | Primary Open Angle Glaucoma (POAG) | - | - |
REGN7041 | Phase 2 | Active Noninfectious Uveitis Affecting the Posterior Segment | - | - |
REGN1908-1909 | Phase 2 | Cat Allergy | - | - |
Marlotamig | Phase 2 | Non-Small Cell Lung Cancer | - | - |
REGN5668 | Phase 2 | Ovarian Cancer | - | - |
Platinum-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
REGN7544 | Phase 2 | Postural Orthostatic Tachycardia Syndrome (POTS) | - | - |
VEGF Trap Eye | Phase 2 | Macular Degeneration | - | - |
REGN10933+REGN10987 combination therapy | Phase 2 | COVID-19 | - | - |
REGN910-3 | Phase 2 | Diabetic Macular Edema | - | - |
REGN7945+Linvoseltamab | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Low-Dose REGN4461 | Phase 2 | Generalized Lipodystrophy | - | - |
REGN10597 | Phase 2 | Melanoma | - | - |
REGN1500 | Phase 2 | Homozygous Familial Hypercholesterolemia | - | - |
AR101 | Phase 2 | Peanut Allergy | - | - |
REGN3918 | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
ALN-CFB | Phase 2 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | - | - |
Olatorepatide | Phase 2 | Overweight or Obesity | - | - |
REGN2477 | Phase 2 | Fibrodysplasia Ossificans Progressiva | - | - |
Timothy Grass SCIT | Phase 2 | Allergic Rhinitis | - | - |
casirivimab+imdevimab | Phase 2 | Healthy | - | - |
PB | Phase 2 | Sepsis-Induced Hypotension | - | - |
REGN5381 | Phase 2 | Heart Failure | - | - |
REGV131 | Phase 2 | Hemophilia B | - | - |
REGN7999 | Phase 2 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | - | - |
ISA101b | Phase 2 | Cervical Cancer | - | - |
Fixed Dose Combination (FDC) cemiplimab+fianlimab | Phase 2 | Melanoma | - | - |
REGN1033 (SAR391786) | Phase 2 | Sarcopenia | - | - |
Vonsetamig | Phase 2 | Chronic Kidney Disease (CKD) | - | - |
REGN5093 | Phase 2 | NSCLC | - | - |
Ubamatamab | Phase 2 | Ovarian Cancer | - | - |
REGN5459 | Phase 2 | Relapsed Multiple Myeloma | - | - |
ALN-SOD | Phase 2 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
REGN13335 | Phase 2 | Pulmonary Arterial Hypertension (PAH) | - | - |
Trevogrumab-Part A | Phase 2 | Obesity | - | - |
BNT116 | Phase 2 | Advanced Non-Small Cell Lung Cancer | - | - |
Tocilizumab | Phase 2 | Recurrent Ovarian Cancer | - | - |
ALN-HSD | Phase 2 | Metabolic Dysfunction-associated Steatohepatitis (MASH) | - | - |
Platinum Doublet | Phase 2 | Non-small Cell Lung Cancer | - | - |
REGN15505+Cemiplimab | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | - | - |
ALN-CIDEB | Phase 2 | Metabolic Dysfunction-Associated Steatotic Liver Disease | - | - |
ALN-PNP | Phase 2 | Healthy Volunteers | - | - |
FDC fianlimab+cemiplimab | Phase 2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | - | - |
Aflibercept Injection | Phase 2 | Diabetic Retinopathy | - | - |
Cemiplimab i.v. on day 1 of cycle | Phase 2 | Merkel Cell Carcinoma, Stage I | - | - |
Pemetrexed (Alimta) | Phase 2 | Pleural Mesotheliomas | - | - |
Enoxaparin | Phase 2 | Venous Thromboembolism | - | - |
Cemiplimab Plus Gemcitabine | Phase 2 | Pancreatic Ductal Adenocarcinoma (mPDAC) | - | - |
ZIV-Aflibercept | Phase 2 | Metastatic Uveal Melanoma | - | - |
Sirolimus | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
Aspirin Challenge | Phase 2 | Aspirin-exacerbated Respiratory Disease | - | - |
RP1 | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
Motixafortide | Phase 2 | Pancreatic Cancer | - | - |
Pexastimogene Devacirepvec (Pexa-Vec) | Phase 2 | Renal Cell Carcinoma | - | - |
Platinum Doublet Chemotherapy (PDC) | Phase 2 | NSCLC | - | - |
VV1 | Phase 2 | Melanoma | - | - |
Dupilumab (blinded) | Phase 2 | Eosinophilic Gastritis | - | - |
Cemiplimab Intravenous | Phase 2 | Clear Cell Renal Cell Carcinoma | - | - |
Carboplatin (AUC 5) | Phase 2 | Pleural Mesotheliomas | - | - |
REGN15505+REGN4336 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | - | - |
fibrodysplasia ossificans progressiva
3 drugs in this indication
Atopic Dermatitis
1 drug in this indication
Multiple Myeloma
1 drug in this indication
ultra-rare 'stone man disease'
1 drug in this indication
Fibrodysplasia Ossificans Progressiva (FOP)
1 drug in this indication
ultra-rare musculoskeletal condition
1 drug in this indication
muscle mass preservation in obesity patients discontinuing GLP-1 therapy
1 drug in this indication
muscle preservation in older patients
1 drug in this indication
Low-grade serous ovarian cancer (LGSOC)
1 drug in this indication
Non-Small Cell Lung Cancer
1 drug in this indication
Paroxysmal Nocturnal Hemoglobinuria
1 drug in this indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
1 drug in this indication
Ovarian Cancer
1 drug in this indication
Metastatic Castration-resistant Prostate Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Regeneron Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 165 drug candidates in Regeneron Pharmaceuticals, Inc.'s (REGN) pipeline across Phase 3, Phase 2, Approved. Its lead program is Cemdisiran (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Regeneron Pharmaceuticals, Inc.'s next FDA catalyst?→
Regeneron Pharmaceuticals, Inc.'s (REGN) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track REGN biotech catalysts?→
Add REGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Regeneron Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.